Access to Healthcare
Patients face barriers to access throughout their journey. Among the most pressing barriers are awareness, diagnostics, funding and healthcare capacity, which stem from broader systemic challenges. These barriers prevent people from receiving the care they need to fight serious diseases and build their future. We at Roche are committed to contribute in overcoming these barriers. Our aim is for every person who needs Roche medicines to be able to access and benefit from them. We believe that in order to achieve this objective a collaborative approach is needed.
Access to healthcare is a shared responsibility and commitment, which requires all stakeholders to work together. To achieve this, we work in various capacities with many different partners to reduce barriers that prevent people from being diagnosed or treated with our medicines. Our overriding objective is improved health outcomes.
What is our approach?
We have a multipronged approach, tailored to the individual healthcare needs of each market, rather than a single, top-down approach.
We provide comprehensive solutions to improve the availability and affordability of our products, strengthen healthcare infrastructure and increase awareness of diseases and healthcare options.
We aim to do this in a way that delivers improvements to healthcare today while allowing us to continue to invest in new medical innovations that can transform patients’ lives tomorrow.
As a leading healthcare company, our goal is to continue to develop innovative medicines and diagnostics that address unmet medical needs and are of real value to society.
We aim to provide real improvements in patients' health and their quality and length of life - this is our core contribution.
For over 120 years, Roche’s primary contribution to improving global healthcare has been researching and developing new medicines and diagnostic tests that deliver significantly better treatment than those currently available. Our aim is to provide sustainable value by improving people’s health and by bringing clear medical and economic benefit to healthcare systems and society. We believe it’s urgent to deliver medical solutions right now – even as we develop innovations for the future. Only by continuing to create value through innovation can we continue to redefine the standard of care and continue to improve health outcomes.
Innovating science in areas of high medical need
We invested 9,9 billion Swiss francs to R&D in 2016 and we are currently the number one healthcare company in R&D investments. Our research and development (R&D) efforts are focused on translating our scientific understandings into new treatments in the areas of oncology, infectious diseases, cardiovascular diseases, metabolism and neuroscience. These disease areas are of epidemic concern globally. As life expectancy rises and lifestyles change they are expected to remain among the greatest burdens, affecting millions of people worldwide. According to the World Health Organisation (WHO), the biggest threat to health in low- and middle-income countries will be posed by chronic diseases such as cancer, cardiovascular disease, diabetes and mental disorders.
That is why we come to work each day. We commit ourselves to scientific rigour, unassailable ethics, and access to medical innovations for all. We do this today to build a better tomorrow. We are proud of who we are, what we do, and how we do it. We are many, working as one across functions, across companies, and across the world.